key: cord-0933738-inh0zcv3
authors: Ceccarelli, Giancarlo; Alessandri, Francesco; Oliva, Alessandra; Dell’Isola, Serena; Rocco, Monica; Ruberto, Franco; Pugliese, Francesco; d’Ettorre, Gabriella; Venditti, Mario
title: Superinfections in patients treated with Teicoplanin as anti‐SARSCoV2 agent
date: 2020-09-30
journal: Eur J Clin Invest
DOI: 10.1111/eci.13418
sha: afe7d7b63468615814b2bd63587c90b67c86d36d
doc_id: 933738
cord_uid: inh0zcv3

We read with interest the paper by Giacobbe et al. estimating a cumulative risk of developing at least one bloodstream infection (BSI) episode (largely due to Gram‐positive pathogens) of almost 50% after 30 days at risk in severe COVID‐19 patients. (2) Similarly, Somers et al. reported an increased risk to develop bacterial superinfections, principally represented by Staphylococcus aureus ventilatory associated pneumonia (VAP), in critically ill patients infected with SARS‐CoV‐2 and treated with Tocilizumab.

This article is protected by copyright. All rights reserved Dear Editor, We read with interest the paper by Giacobbe et al. estimating 

Bloodstream infections in critically ill patients with COVID-19

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Is teicoplanin a complementary treatment option for COVID-19? The question remains